A bright future for multiple myeloma
A bright future for multiple myeloma Huge advancements have been made in treating multiple myeloma (MM) using immunomodulatory drugs such as proteasome inhibitors, monoclonal antibodies and HDAC inhibitors. However, Kenneth Anderson, MD, of the Dana-Farber Cancer Institute, Boston, MA, tells us to stay seated, as the future is even brighter! By developing novel agents targeting […]
Read More